Bedsure marks 10 years of comfort with a CSR commitment to support families and advance sustainability

NEW YORK, Dec. 11, 2025 /PRNewswire/ — Bedsure, a leading woman-owned home textiles brand, is partnering with Ronald McDonald House Charities Upper Midwest (RMHC-UM) to provide warmth and comfort to families of critically ill or injured children. Bedsure donated nearly 800 premium bedding products, including its GentleSoft® Sheet Sets, to RMHC-UM’s facilities, helping to support the warm, welcoming “Home Away from Home” environment for families during challenging times.

“We are honored to support Ronald McDonald House Charities’ mission of supporting families when they need it most,” said Eric Lin, Chief Marketing Officer for Bedsure. “This donation reflects our gratitude to the community and our customers, as well as our ongoing commitment to bring comfort to every home.”

The donation ceremony was held at RMHC-UM’s main building in Minneapolis on December 9, featuring speeches from both Bedsure and RMHC-UM representatives emphasizing the importance of this partnership and the power of community.

As Bedsure honors its 10^th anniversary, it continues its dedication to providing softness and comfort to families across the world. This initiative underscores Bedsure’s dedication to social responsibility and its commitment to spreading warmth and compassion beyond the home.

Bedsure’s Broader Commitment to Giving Back

Beyond its partnership with RMHC-UM, Bedsure actively demonstrates its commitment to giving back through ongoing community giving initiatives. In 2025 alone, the brand donated products to organizations such as the National Breast Cancer Foundation and continues to champion sustainability through its GentleSoft® collection. By collaborating with ethical manufacturers that promote gender equality, create employment opportunities for people with disabilities, and support educational opportunities, Bedsure ensures that every product reflects its mission of creating positive social impact.

About Bedsure

Founded in 2016, Bedsure is a leading home textile brand with products sold to over 40 million customers worldwide. Bedsure has over 50 bestselling home products in 8 countries and has maintained a compound growth rate of 100% for five consecutive years. While Bedsure has grown into a global company with a diverse range of products to meet various customer needs, its focus on providing comfortable home products and everyday value remains unchanged. For more information, visit Bedsure’s official website https://bedsurehome.com/, or Amazon shop. Stay in touch with Bedsure on social media @bedsurehome.

About Ronald McDonald House Charities Upper Midwest
Ronald McDonald House Charities, Upper Midwest is a 501 (c) (3) organization that provides a comfortable and caring home away from home that supports keeping families together and reduces stress during a child’s serious illness. Based in Minneapolis, the organization operates five locations in Minnesota and has served over 5,700 families in the last year alone. Additional information can be found at https://www.rmhc-uppermidwest.org/.

KUALA LUMPUR, Malaysia, Dec. 11, 2025 /PRNewswire/ — GIBO Holdings Ltd. (NASDAQ: GIBO) today announced its strategic initiative to develop Malaysia’s first phase of a high-performance AI data center, beginning with a 30MW deployment featuring a 14,000-GPU supercomputing cluster. Purpose-built for industrial-scale AI development and deployment, the facility will support large language model (LLM) training, small and mid-sized model development, and large-scale inference workloads for both commercial and public-sector use cases. This development represents a major step forward in strengthening Malaysia’s digital infrastructure capabilities and accelerating its emergence as a major AI compute hub within the Asia-Pacific region.

The planned 14,000-GPU cluster will be designed to deliver high-density computing optimized for deep learning, multimodal AI systems, simulation workloads, and next-generation AI applications. Once operational, the facility is expected to become one of the most advanced compute environments in Malaysia, enabling AI-driven research, public-private innovation programs, and enterprise deployment at scale across multiple industries including mobility systems, advanced manufacturing, fintech, healthcare, cybersecurity, agriculture, creative media, robotics, and sustainability technology.

This initiative forms the first milestone in GIBO’s long-term roadmap to scale its AI infrastructure strategy from the initial 30MW to a 100MW multi-zone AI compute campus, and subsequently to a 200MW regional flagship facility. The broader vision includes establishing a multi-location interconnected network of AI-focused data centers spanning key regions across Malaysia, including Sarawak, Johor, Penang and Greater Kuala Lumpur. Once complete, this network is intended to serve as a unified compute backbone connecting Malaysia to Singapore, Indonesia, Thailand, Japan, Korea and Greater China, creating what GIBO describes as an “ASEAN-to-North Asia AI Compute Highway.”

Engineered with a sustainability-aligned architecture, the data center will incorporate next-generation liquid or immersion cooling methodologies designed to maximize energy efficiency and operational resilience in tropical conditions. The infrastructure will support full-spectrum model training, including trillion-parameter architectures, while reducing compute costs for enterprises and accelerating adoption of AI systems across commercial and industrial sectors. Dedicated digital pipelines will be integrated for sector-specific applications, enabling the rapid development and deployment of specialized AI systems tailored to real-world use cases.

Malaysia’s strategic regional position, maturing digital ecosystem, pro-AI national policies, and rapidly advancing technology talent pool make it a competitive environment for AI infrastructure expansion. GIBO expects that the project will become a catalytic anchor for broader innovation, attracting global AI companies, ecosystem partners, and next-generation technology ventures to the country.

With construction planning underway, this 30MW deployment represents the foundational phase of GIBO’s ambition to build one of the largest AI-specific data center networks in the region within the next three to five years. Through this initiative, GIBO aims to support the growing global demand for compute power, accelerate the deployment of intelligent systems across industries, and position Malaysia as a central node in the future global AI economy.

About GIBO Holdings Limited

GIBO Holdings Ltd. is a unique and integrated AIGC animation streaming platform with extensive functionalities provided to both viewers and creators that serves a broad community of young people across Asia to create, publish, share and enjoy AI-generated animation video content. With over 83 million registered users and advanced AI-powered tools, GIBO seeks to redefine the landscape of digital content creation.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, the Company’s advantages and expected growth, the Company’s ability to source and retain talent, and the Company’s cash position, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.

Contact Information

Investor Relations:
Bill Zima
ICR, Inc.
William.zima@icrinc.com 

Media Relations:
Edmond Lococo
ICR, Inc.
Edmond.Lococo@icrinc.com

For more information and the latest updates, please visit:
 https://www.globalibo.com/gibo-click/

International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors

TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its first-ever oral presentation of clinical data at an international oncology congress, following its prior preclinical oral presentation of HCB101 at CSCO 2022.

The ESMO Immuno-Oncology Congress is Europe’s premier meeting dedicated exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.

Presentation Details:

Abstract ID: 242MO
Title: HCB101, a Differentiated SIRPα Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and Lymphoma
First Author: Dr. Fangling Ning, Affiliated Hospital of Binzhou Medical University
Date / Time: 11 December 2025 / 11:45 – 12:45 GMT
Location: Whittle Room, Queen Elizabeth II Centre, London
Presenter: Alvin Luk, PhD, MBA, CCRA – President & CMO (Group) and CEO (U.S.A.), TIME100 Health 2025 Honoree

“For nearly a decade, CD47 therapies were held back not by flawed biology but by flawed molecules, which struggled to balance safety and efficacy at the same time, especially in immunologically cold tumors,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “HCB101 was engineered from the ground up to solve that problem. Using AI-guided structural modeling, we identified three core mutations that reshape SIRPα’s interaction with CD47, allowing us to combine the strengths of first- and second-generation approaches into a single, differentiated molecule. Being selected as one of only 26 mini-oral presentations at ESMO Immuno-Oncology reinforces the field’s recognition of this effort and redefines the CD47 therapies. With its clean safety profile, strong target engagement, and early activity in cold tumors, HCB101 is emerging as a true macrophage-checkpoint backbone – much like the transformative PD-1/PD-L1 therapies that were based on T-cell checkpoint inhibition.”

Key Findings Highlighted in the Mini-Oral

Monotherapy (HCB101-101; NCT05892718)

• Clean, cytopenia-sparing safety across 12 cohorts up to 36 mg/kg QW
• No bleeding events or immune-related toxicities, with the majority of treatment-related adverse events being Grade 1-2
• Linear PK (T_1/2 ~3 days) with receptor occupancy (RO) >99% at ≥8 mg/kg
• Durable antitumor activity, including confirmed PRs in:
  • HNSCC -Head and neck squamous cell carcinoma (~42% tumor regression, ≥32 weeks)
  • MZL – Marginal zone lymphoma (~89% tumor regression, ≥16 weeks)
• Stable disease ≥4-9 months across colorectal cancer (CRC), ovarian cancer, non-small cell lung cancer (NSCLC), and sarcoma
• Combination Therapy (HCB101-201; NCT06771622)
• Well-tolerated across gastric cancer (GC), triple-negative breast cancer (TNBC), CRC, and HNSCC
• No new safety signals across all evaluated combinations
• Cytopenias fully attributable to chemotherapy, not HCB101
• 2L GC:
  • 58.3% ORR (7/12) for all cohorts evaluated, 77.8% ORR (7/9) for mid-dose cohorts, and 100% DCR
  • Tumor shrinkage up to -78.2%
• 1L HER2+ GC: 33% ORR (1/3)
• 1L TNBC: 50% ORR (3/6) and 100% DCR

Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and Chief Executive Officer (U.S.A.) of HanchorBio, added, “The early efficacy signals from HCB101 are unusually compelling for this stage of development. In second-line GC, where standard therapy achieves an ORR of about 27%, HCB101 combinations exceed 78% ORR, achieve 100% disease control, and result in tumor reduction approaching -78%. These results are not incremental; they meaningfully exceed expectations and reflect robust macrophage checkpoint engagement. With clean safety and sustained receptor occupancy, the data give us confidence to anchor development in second-line disease and expand into first-line and perioperative settings where depth and durability of response matter most.”

About HCB101: A Next-Generation SIRPα Fc-Fusion Protein

HCB101 is a 3.5^th-generation engineered SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s FBDB™ platform to selectively target tumor CD47 while minimizing binding to red blood cells. This design avoids the anemia and thrombocytopenia that limited early anti-CD47 programs, while preserving potent macrophage activation and downstream T-cell engagement. Key differentiators include:

• Cytopenia-sparing safety up to 30-36 mg/kg
• Receptor occupancy (RO) >99% at clinically active exposures
• Strong macrophage and downstream T-cell activation
• Broad antitumor activity across >80 PDX/CDX models and multiple clinical tumor types
• Robust early combination efficacy in tumors that historically respond poorly to immunotherapy

Unlike earlier approaches, HCB101’s safety, target selectivity, and RO profile support its use as a macrophage-checkpoint backbone – analogous to how PD-1/PD-L1 inhibitors function as foundational T-cell backbones in oncology. HCB101 is designed for broad combinability across established and emerging treatment modalities, including:

• Chemotherapy
• Antibody-drug conjugates (ADCs)
• Anti-PD-1/anti-PD-L1 checkpoint inhibitors
• Anti-VEGF inhibitors
• Anti-EGFR therapies
• Anti-HER2 regimens

This versatility positions HCB101 as a modular, next-generational immuno-oncology component capable of enhancing the efficacy of multiple therapeutic backbones across solid tumors and hematologic malignancies.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite the landscape of cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs in multi-functional, innovative molecular configurations in R&D and improving CMC manufacturing processes, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: https://www.hanchorbio.com/

• O-RAN ALLIANCE PlugFests offer collaborative environment to accelerate the development of open and intelligent RAN-based solutions
• The O-RAN Global PlugFest Fall 2025 showcased advances in automation, network optimization, energy efficiency, and security – many featuring AI in the RAN
• The Fall 2025 PlugFest was co-hosted by 25 operators, OTICs and institutions in 19 labs worldwide – with a total of 64 companies and institutions participating

BONN, Germany, Dec. 11, 2025 /PRNewswire/ — The O-RAN ALLIANCE (O-RAN) today announced successful completion of the O-RAN Global PlugFest Fall 2025.

O-RAN PlugFests are designed to accelerate the development of O-RAN based products and solutions by offering structured testing and integration opportunities in a neutral and collaborative environment.

Building on the momentum of previous PlugFests, the Fall 2025 event showcased continued evolution of open, intelligent, virtualized and interoperable Radio Access Network (RAN) solutions – with advances in automation, end-to-end integration of multi-vendor solutions, network optimization, energy efficiency, security, and more.

The Fall 2025 PlugFest showcased O-RAN performance in advanced scenarios like autonomous network operation agent, Distributed Antenna Systems (DAS) and O-RAN deployment for high-speed trains. Proofs of concept were conducted on compact GenAI models for O-RAN testing. Several scenarios were tested in live networks, and some are already being adopted in commercial operation.

O-RAN Global PlugFest Fall 2025 was hosted by 25 operators, Open Testing and Integration Centres (OTICs) and independent institutions in 19 labs worldwide. It was conducted from August to November 2025 with a total of 64 companies that took part, some of which involved in multiple venues.

“Our regular PlugFests provide incentives to diverse companies and institutions in the RAN industry to mature innovative O-RAN based solutions,” said Chih-Lin I, Co-chair of O-RAN ALLIANCE’s Technical Steering Committee and China Mobile Chief Scientist, Wireless Technologies, China Mobile Research Institute. “We are pleased to see demonstrations of readiness of many multi-vendor O-RAN deployments, and also advanced use cases and scenarios featuring AI in the RAN. A big thank you to all hosts, labs and participants for their great efforts and achievements.”

Participants in O-RAN ALLIANCE Global PlugFest Fall 2025

O-RAN ALLIANCE appreciates high interest from the community in testing and integration at the O-RAN Global PlugFest Fall 2025 and would like to recognize hosts, labs and participants, including:

1Finity, Accuver, Airhop Communications, AmpliTech Group, ANDREW – an Amphenol Company, AT&T, Calnex Solutions, DeepSig, Dell Technologies, Deutsche Telekom, Digital Catapult, EANTC, Eridan Communications, ETRI, EURECOM, G Reigns, Gigalane, HCL Technologies, HFR, HPE, i14y Lab, Intel, Iowa State University (ARA), IS-Wireless, Industrial Technology Research Institute (ITRI), KDDI, Keysight Technologies, Korea Telecom, Kumoh National Institute of Technology, LG Electronics, LG Uplus, LIONS Technology, LITE-ON Technology, NEC, Nokia, North Carolina State University (AERPAW), Northeastern University, NTT DOCOMO, Orange, Pegatron, Quanta Cloud Technology (QCT), Rakuten Mobile, Rakuten Symphony, Red Hat, Rohde & Schwarz, Rutgers University (COSMOS/WINLAB), Samji Electronics, Singapore University of Technology and Design (SUTD), SK Telecom, SoftBank, Software Radio Systems, SOLiD, Super Micro, TIM, TTA, University of New Hampshire Interoperability Labs (UNH-IOL), University of Utah (POWDER), Verizon, VIAVI Solutions, Vodafone, VVDN Technologies, Wave Electronics, Wind River, YRP R&D Promotion Committee.

About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.

O-RAN ALLIANCE PlugFest

MIAMI, Dec. 11, 2025 /PRNewswire/ — MATELASER, INC., a pioneer in mobile laser therapy, today announced the official launch of its global crowdfunding campaign for the W1 REGEN, a breakthrough device that brings clinic-grade laser therapy into an ultra-miniature 24g wearable form. Priced at just $99, W1 REGEN officially breaks the cost barrier for true medical-grade photobiomodulation, marking a major step forward in the consumerization of laser therapy.

A New Category: Pocket-Sized, Deep-Tissue Laser Therapy

Unlike large LED-panel “red light masks” and low-irradiance consumer gadgets, the W1 REGEN delivers 5100 mW/cm² via dual-wavelength VCSEL architecture (US patent pending), engineered for muscle, tendon, joint and bone-level penetration.

Early Validation at Bryan Johnson’s “Don’t Die Summit”

On December 7, just days before its official Kickstarter launch, the W1 REGEN debuted at Bryan Johnson’s “Don’t Die Summit,” drawing intense interest from bio-optimization leaders, longevity researchers, and elite recovery specialists. Attendees expressed immediate purchasing intent, reinforcing the device’s emergence as a credible tool in evidence-driven performance medicine.

Who It Helps — and Why It Matters

The W1 REGEN was engineered for users who need real therapeutic depth, not cosmetic glow:

• Endurance athletes & marathon runners
• Chronic lower-back & cervical tension sufferers
• Post-surgical tissue healing
• Tendinitis, tennis elbow, runner’s knee
• Office-based inflammation & scapular tightness
• Aging-related joint discomfort & microvascular decline

From recovery labs to living rooms, deep-penetration laser therapy is now portable.

Experience the W1 REGEN at CES 2026

Building on momentum from the Summit and Kickstarter activation, MATELASER will showcase the full Unbound wearable recovery ecosystem at CES.

Date: January 6-9, 2026
Location: Venetian Expo, Halls A-D
Booth: 56549

Kickstarter Campaign Details

The W1 REGEN is now live on Kickstarter. Backers can secure early bird pricing and become the first users to join MATELASER’s “Unbound” pain management ecosystem.

To learn more or support the campaign, Kickstarter: Search ‘W1 REGEN’

About MATELASER, INC.

Headquartered in Miami, MATELASER, INC. is an FDA-certified manufacturer specializing in mobile and professional laser therapy systems. With decades of leadership in photobiomodulation engineering, the company is committed to making clinically effective laser therapy safe, accessible, and affordable for everyday users worldwide.